The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor
More
The FINANCIAL – The devastation came overnight on the day Tennessee participated in the Super Tuesday presidential primary. East Nashville residents only had 6 minutes to prepare and get to safety. The tornadoes destroyed at least 48 buildings and left about 50,000
More